International definition of iMCD-TAFRO: future perspectives

Since thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome was first proposed in 2010, there has been considerable progress in this area, particularly regarding its association with idiopathic multicentric Castleman disease (iMCD). TAFRO syndr...

Full description

Saved in:
Bibliographic Details
Published inJournal of Clinical and Experimental Hematopathology Vol. 62; no. 2; pp. 73 - 78
Main Authors Nishimura, Yoshito, Nishimura, Midori Filiz, Sato, Yasuharu
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society for Lymphoreticular Tissue Research 01.01.2022
JSLRT
Subjects
idiopathic multicentric Castleman disease
iMCD-TAFRO
Review
TAFRO syndrome
TAFRO syndrome
idiopathic multicentric Castleman disease
iMCD-TAFRO
Online AccessGet full text

Cover

More Information
Summary:Since thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome was first proposed in 2010, there has been considerable progress in this area, particularly regarding its association with idiopathic multicentric Castleman disease (iMCD). TAFRO syndrome is a heterogeneous category with a constellation of symptoms that can develop in the setting of infection, rheumatologic disorder, malignancy, and iMCD. Now, iMCD with TAFRO symptoms is subtyped as iMCD-TAFRO. However, confusion between TAFRO syndrome and iMCD-TAFRO remains. In this article, we discuss the current understanding and future research agenda of TAFRO syndrome and iMCD-TAFRO from the perspective of its new validated international definition.
ISSN:1346-4280
1880-9952
DOI:10.3960/jslrt.21037